LYTAK1, a TAK1 inhibitor, suppresses proliferation and epithelial‑mesenchymal transition in retinal pigment epithelium cells

Chen,Zhen; Mei,Yan; Lei,Huo; Tian,Run; Ni,Ninghua; Han,Fang; Gan,Shengwei; Sun,Shanquan

doi:10.3892/mmr.2016.5275

LYTAK1, a TAK1 inhibitor, suppresses proliferation and epithelial‑mesenchymal transition in retinal pigment epithelium cells

Authors:
- Zhen Chen
- Yan Mei
- Huo Lei
- Run Tian
- Ninghua Ni
- Fang Han
- Shengwei Gan
- Shanquan Sun
View Affiliations

Affiliations: Department of Cell Engineering and Biological Engineering, Chongqing Medical University, Chongqing 400016, P.R. China, Department of Ophthalmology, The First People's Hospital of Yunnan, Kunming, Yunnan 650032, P.R. China
Published online on: May 13, 2016 https://doi.org/10.3892/mmr.2016.5275
Pages: 145-150
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The proliferation of retinal pigment epithelium (RPE) cells following epithelial‑mesenchymal transition (EMT) is critical in proliferative vitreoretinopathy (PVR), which results in retinal detachment and the loss of vision. The current study was conducted to examine the importance of transforming growth factor β‑1 (TGF‑β1)‑activated kinase 1 (TAK1) inhibitor (LYTAK1) in regulating EMT and the proliferation of RPE cells. RPE cells were pre-treated with increasing concentrations of LYTAK1 prior to treatment with TGF‑β1 for 24 h. The effect of LYTAK1 on RPE cell proliferation was examined using a Cell Counting kit‑8 assay. The expression levels of TAK1, smooth muscle actin, fibronectin, p-Smad2, p-Smad3, nuclear factor (NF)-κB p65 and IκB kinase α were detected by western blotting. LYTAK1 suppressed the proliferation and migration of RPE cells. Additionally, LYTAK1 significantly prevented TGF‑β1‑induced EMT by decreasing the levels of fibronectin and α‑smooth muscle actin. It was demonstrated that the effects of LYTAK1 were via the Smad signaling pathway. The present study also determined, that the underlying mechanism of the effects of LYTAK1 on EMT in RPE cells involves downregulation of the NF‑κB signaling pathway. In conclusion, TAK1 transcription factor was shown to be important in TGF‑β1‑induced EMT in human RPE cells. Thus, the results of this study aid in elucidating the pathogenesis of human PVR. In addition, this study suggests that specific inhibition by LYTAK1 may provide a novel approach for the treatment and prevention of PVR.

View Figures

View References

1	Bharti K, Nguyen MT, Skuntz S, Bertuzzi S and Arnheiter H: The other pigment cell: Specification and development of the pigmented epithelium of the vertebrate eye. Pigment Cell Res. 19:380–394. 2006. View Article : Google Scholar : PubMed/NCBI
2	Strauss O: The retinal pigment epithelium in visual function. Physiol Rev. 85:845–881. 2005. View Article : Google Scholar : PubMed/NCBI
3	Takahashi E, Nagano O, Ishimoto T, Yae T, Suzuki Y, Shinoda T, Nakamura S, Niwa S, Ikeda S, Koga H, et al: Tumor necrosis factor-alpha regulates transforming growth factor-beta-dependent epithelial-mesenchymal transition by promoting hyaluronan-CD44-moesin interaction. J Biol Chem. 285:4060–4073. 2010. View Article : Google Scholar
4	Garweg JG, Tappeiner C and Halberstadt M: Pathophysiology of proliferative vitreoretinopathy in retinal detachment. Surv Ophthalmol. 58:321–329. 2013. View Article : Google Scholar : PubMed/NCBI
5	Lamouille S and Derynck R: Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol. 178:437–451. 2007. View Article : Google Scholar : PubMed/NCBI
6	Saika S: TGFbeta pathobiology in the eye. Lab Invest. 86:106–115. 2006. View Article : Google Scholar
7	Desmoulière A, Geinoz A, Gabbiani F and Gabbiani G: Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol. 122:103–111. 1993. View Article : Google Scholar : PubMed/NCBI
8	Yoon YS, Lee JH, Hwang SC, Choi KS and Yoon G: TGF beta1 induces prolonged mitochondrial ROS generation through decreased complex IV activity with senescent arrest in Mv1Lu cells. Oncogene. 24:1895–1903. 2005. View Article : Google Scholar : PubMed/NCBI
9	Mu Y, Gudey SK and Landström M: Non-Smad signaling pathways. Cell Tissue Res. 347:11–20. 2012. View Article : Google Scholar
10	Kim SI, Kwak JH, Na HJ, Kim JK, Ding Y and Choi ME: Transforming growth factor-beta (TGF-beta1) activates TAK1 via TAB1-mediated autophosphorylation, independent of TGF-beta receptor kinase activity in mesangial cells. J Biol Chem. 284:22285–22296. 2009. View Article : Google Scholar : PubMed/NCBI
11	Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, Kawai T, Matsumoto K, Takeuchi O and Akira S: Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol. 6:1087–1095. 2005. View Article : Google Scholar : PubMed/NCBI
12	Hanada M, Ninomiya-Tsuji J, Komaki K, Ohnishi M, Katsura K, Kanamaru R, Matsumoto K and Tamura S: Regulation of the TAK1 signaling pathway by protein phosphatase 2C. J Biol Chem. 276:5753–5759. 2001. View Article : Google Scholar
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
14	Kalluri R: EMT: When epithelial cells decide to become mesenchymal-like cells. J Clin Invest. 119:1417–1419. 2009. View Article : Google Scholar : PubMed/NCBI
15	García S, López E and López-Colomé AM: Glutamate accelerates RPE cell proliferation through ERK1/2 activation via distinct receptor-specific mechanisms. J Cell Biochem. 104:377–390. 2008. View Article : Google Scholar
16	Palma-Nicolás JP, López E and López-Colomé AM: Thrombin stimulates RPE cell motility by PKC-zeta-and NF-kappa B-dependent gene expression of MCP-1 and CINC-1/GRO chemokines. J Cell Biochem. 110:948–967. 2010. View Article : Google Scholar
17	Adhikari A, Xu M and Chen ZJ: Ubiquitin-mediated activation of TAK1 and IKK. Oncogene. 26:3214–3226. 2007. View Article : Google Scholar : PubMed/NCBI
18	Sakurai H: Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci. 33:522–530. 2012. View Article : Google Scholar : PubMed/NCBI
19	Melisi D, Xia Q, Paradiso G, Ling J, Moccia T, Carbone C, Budillon A, Abbruzzese JL and Chiao PJ: Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J Natl Cancer Inst. 103:1190–1204. 2011. View Article : Google Scholar : PubMed/NCBI
20	Singh A, Sweeney MF, Yu M, Burger A, Greninger P, Benes C, Haber DA and Settleman J: TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell. 148:639–650. 2012. View Article : Google Scholar : PubMed/NCBI
21	Neil JR, Tian M and Schiemann WP: X-linked inhibitor of apoptosis protein and its E3 gene ligase activity promote transforming growth factor-beta-mediated nuclear factor-kappaB activation during breast cancer progression. J Biol Chem. 284:21209–21217. 2009. View Article : Google Scholar : PubMed/NCBI
22	Landström M: The TAK1-TRAF6 signalling pathway. Int J Biochem Cell Biol. 42:585–589. 2010. View Article : Google Scholar : PubMed/NCBI
23	Akhurst RJ and Hata A: Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov. 11:790–811. 2012. View Article : Google Scholar : PubMed/NCBI
24	Huber MA, Azoitei N, Baumann B, Grünert S, Sommer A, Pehamberger H, Kraut N, Beug H and Wirth T: NF-κappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest. 114:569–581. 2004. View Article : Google Scholar : PubMed/NCBI